pharma · Triple-Negative Breast Cancer (TNBC) · TELO
Telomir Pharmaceuticals
Telomir Pharmaceuticals is a pharma organization headquartered in Tampa, USA. It trades on NYSE under ticker TELO. Primary therapeutic focus areas include Triple-Negative Breast Cancer (TNBC). NovaPharmaNews links 1 clin
Tampa, USA HQ
2022 Founded
6 Employees
Public company Type
TELO · NYSE Ticker
Company details
- Status
- Public
- HQ
- Tampa, USA
- Founded
- 2022
- Employees
- 6
- Programs
- 1
- Drugs
- 0
- Patents
- 0
Zn-Telomir
Phase 2 · small molecule · Triple-Negative Breast Cancer (TNBC)
Zn-Telomir for Triple-Negative Breast Cancer (TNBC) is a Phase 2 program (small_molecule) at Telomir Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code TELO-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Telomir Pharmaceuticals
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Triple-Negative Breast Cancer (TNBC)
- Status
- active
- Trials
- 1